Is NXY-059 beneficial in ischemic stroke?
Rebecca Ireland
This article has no abstract so we have provided the first paragraph of the full text.
Acute ischemic stroke is a major cause of death in industrialized countries and is usually treated with thrombolysis using alteplase. This treatment, however, must be started within 3 h of stroke onset, and can cause bleeding. A recent randomized, placebo-controlled trial investigated clinical use of NXY-059, an agent that has been shown to reduce infarct size and preserve brain function in animal models of stroke.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.